中國人壽(601628.SH):2024年歸母淨利潤1069.35億元,同比增長108.9%
格隆匯3月26日丨中國人壽(601628.SH)公佈,2024年實現營業收入5285.67億元,同比增長30.5%;歸屬於母公司股東的淨利潤1069.35億元,同比增長108.9%。公司擬向全體股東派發2024年末期現金股利每股人民幣0.45元(含税),共計約人民幣127.19億元;連同已派發的2024年中期現金股利,全年現金股利為每股人民幣0.65元(含税),共計約人民幣183.72億元。
截至報吿期末,總資產、投資資產雙雙突破6萬億元,分別達6.77萬億元和6.61萬億元,歸屬於母公司股東的股東權益首次突破5000億元,達5096.75 億元,同比大幅增長55.5%;綜合償付能力充足率達207.76%,核心償付能力充足率達153.34%,保持高位穩定; 內含價值超1.4萬億元,穩居行業首位;公司擁有長險有效保單件數達3.26億份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.